JUN 13, 2019 08:23 AM PDT

This Molecule Compound Reduces Chemo Resistance

WRITTEN BY: Julia Travers

Drug resistance is a major hindrance to cancer treatment. Researchers from Duke University, MIT and the University of Rhode Island have zeroed in on a molecule compound that works as a kind of glue, binding and incapacitating a protein that helps cancer cells adapt to and resist chemo treatments. Pei Zhou, Ph.D., a professor of biochemistry at Duke and senior co-author of the new study on reducing chemo-resistance, is excited about he and his colleagues’ discoveries.

"Chemotherapies are often effective the first time around, but then the cancers mutate and become resistant to that drug and the next, and the next. It reminds me of Boggarts, those shapeshifting creatures from ‘Harry Potter’ that morph from one scary thing to another. The beauty of this approach is that you essentially freeze the Boggart in its current form, so you can kill it off for good,” Zhou said.

Previous studies identified a protein named Rev1 as a key player in cancer cell’s ability to change and resist chemotherapy drugs like cisplatin, which are designed to keep the cancer cells from replicating. Rev1 has already been successfully disrupted through genetic means at the labs of two other senior co-authors, Graham C. Walker and Michael T. Hemann at MIT. But the new team wanted to find a molecule compound that could block or inhibit Rev1. So, they tested 10,000 small molecule compounds and discovered JH-RE-06.

When Rev1 interacts with JH-RE-06, it joins with or “dimerizes” with another copy of itself. When Rev1 is bound and locked in this way, it can’t help cancer cells shift forms and resist treatment.

molecule illustrations, credit: public domain

In human cancer cell lines, the new molecule was found to enhance the effectiveness of multiple kinds of chemotherapy and to suppress cancer’s mutant abilities. In a mouse model of human melanoma treated with cisplatin and JH-RE-06, the tumors stopped growing, and the mice survived longer.

"This is a great proof of principle that it is possible to target this protein, but we have a lot of work to do to turn this lead compound into a viable candidate that we can take to the clinic,” senior study co-author Jiyong Hong, Ph.D., a professor of chemistry at Duke, said.

 

Sources: Science Daily, Cell

About the Author
  • Julia Travers is a writer, artist and teacher. She frequently covers science, tech and conservation.
You May Also Like
JUL 17, 2019
Cancer
JUL 17, 2019
Make sure you schedule a morning appointment with your doctor
You may want to reschedule that late afternoon doctor’s appointment. A new study published today in JAMA Network Open suggests that primary care doct...
JUL 17, 2019
Cancer
JUL 17, 2019
A poor gut microbiome could cause breast cancer to spread
New research from the University of Virginia Cancer Center and recently published in the journal Cancer Research suggests that an unhealthy gut microbiome ...
JUL 17, 2019
Cancer
JUL 17, 2019
Proton Therapy May Reduce Second Cancer Risk More Than Other Radiation Types
A new study finds that proton beam radiation therapy (PBRT) might lead to a reduction in the risk for a second cancer, when compared to other types of cont...
JUL 17, 2019
Cancer
JUL 17, 2019
Post-breast cancer women have a higher risk of heart disease
Can’t women get a break? Apparently not, according to new research from the Botucatu Medical School at Paulista State University in Sao Paulo, Brazil...
JUL 17, 2019
Cancer
JUL 17, 2019
Turmeric Slows Bone Cancer
Often found in South Asian meals, the spice turmeric comes from a ginger-like plant. Turmeric and its principal ingredient, curcumin, have many beneficial ...
JUL 17, 2019
Cancer
JUL 17, 2019
Will Light Therapy Edge Out Opioids for Cancer Mouth Pain?
Photobiomodulation therapy, a form of low-dose light therapy, has now been found to be one of the best ways to treat the pain of oral mucositis, the mouth ...
Loading Comments...